N-Glycosylation-Defective Splice Variants of Neuropilin-1 Promote Metastasis by Activating Endosomal Signals by Huang, Xiuping et al.
Supplementary Information 
 
N-glycosylation-defective splice variants of neuropilin-1 promote metastasis by activating 
endosomal signals 
 























































Supplementary Figure 1. Alignment of NRP1-WT, NRP1-ΔE4 and NRP1-ΔE5 amino acid sequences. 
The character N highlighted with yellow indicates the putative N-linked glycosylation sites of NRP1. 
 
 
Supplementary Figure 2. NRP1-∆E4 and NRP1-∆E5 are expressed in punctate cytoplasmic 
structures under basal conditions. (a) RT-PCR analysis of NRP1-WT mRNA expression in normal 
colonic mucosa was performed using the two-fold increased RNA amount than those used in Fig. 1e. (b) 
Western blot analysis of the indicated CRC cell lines. (c, d) Confocal images of NRP1 with DAPI staining 
in HCT116 (c) and HT29 (d) cells transfected with NRP1-WT, NRP1-∆E4 or NRP1-∆E5 for 24 h and 48 h. 
Scale bars, 10 µm. (e) Cell lysates were prepared from the primary CRC cell lines (Pt93, Pt130, Pt2237 
and LM2237) and analyzed by western blot for the indicated proteins. The lysates of HCT116 cells 
expressing NRP1-WT, NRP1-ΔE5 and NRP1-ΔE4 were used as positive controls for the western blot 
analysis. (f) Confocal images of NRP1 with DAPI staining in the indicated primary CRC cells. Scale bars, 
10 µm. (g) Confocal images of NRP1 with DAPI staining in serum-starved (-FBS) HT29 cells and the cells 
stimulated with HGF antibody- or control IgG-neutralized FBS for 30 min. Scale bars, 10 µm. (h) 
Quantification of HGF levels in FBS neutralized with HGF antibody or control IgG using sandwich ELISA. 




































Supplementary Figure 3. NRP1-∆E4 and NRP1-∆E5 co-localize with endosomal and recycling 
markers and exhibit a defective degradation. (a, b) Confocal images of NRP1, transferrin, Rab4, Rab11, 
lysotracker, cathepsin D and DAPI staining in HT29 cells with expression of the indicated NRP1 isoforms. 
Scale bars, 10 µm. (c) Quantification of co-localization between lysotracker or cathepsin D and the 
indicated NRP1 isoforms as shown in (b). (d) Confocal images of NRP1, EEA1, Rab7, transferrin and 
DAPI staining in HCT116 cells with expression of the indicated NRP1 isoforms. Scale bars, 10 µm. (e) 
Quantification of co-localization between the indicated NRP1 isoforms and the endosomal markers EEA1, 
Rab7 or transferrin as shown in (d). (f) Confocal images of NRP1, lysotracker, cathepsin D and DAPI 
staining in HCT116 cells with expression of the indicated NRP1 isoforms. Scale bars, 10 µm. (g) 
Quantification of co-localization between lysotracker or cathepsin D and the indicated NRP1 isoforms as 
shown in (f). (h) Confocal images of NRP1, Rab7 and DAPI staining in the indicated primary CRC cells. 
Scale bars, 10 µm. (i) Serum-starved HCT116 cells with expression of the indicated NRP1 isoforms were 
pretreated with 50 μg ml-1 cycloheximide and stimulated with HGF (50 ng ml-1) for the indicated times 
followed by western blot analysis. (j) The western blots of NRP1 shown in (i) were quantified using Image 
J software. The level of NRP1 remaining was obtained by normalizing to the β-actin level at each time 
point. All graphic data are presented as mean ± s.e.m. (n=3 independent experiments). *p < 0.003 using 































Supplementary Figure 4. Defect in N150- or N261-linked glycosylation is critical for NRP1 
internalization and accumulation. (a) Confocal images of NRP1 with DAPI staining in HT29 cells with 
stable expression of NRP1-WT or the indicated mutants. Scale bars, 10 µm. (b) Confocal images of NRP1 
with DAPI staining in HCT116 cells transfected with NRP1-WT or the indicated mutants for 24 h and 48 h. 
Scale bars, 10 µm. (c) HCT116 cells with transient expression of NRP1-WT or the indicated mutants were 
treated with 50 μg ml-1 cycloheximide (CHX) for the indicated times followed by western blot analysis. (d) 
Western blots of NRP1 as shown in (c) were quantified using Image J software. The level of NRP1 
remaining was obtained by normalizing to the β-actin level at each time point. Data are presented as mean 
± s.e.m. (n=3 independent experiments). *p < 0.001 using Student’s t-test. (e) Confocal images of NRP1 
with DAPI staining in the serum-satrved HT29 cells with expression of the indicated NRP1 isoforms, 






































Supplementary Figure 5. NRP1-∆E4 and NRP1-∆E5 promote CRC cell migration and invasion. (a) 
HCT116 cells with stable expression of NRP1-WT, NRP1-∆E4, NRP1-∆E5 or vector control were assessed 
for cell growth over 3 days. (b) Migration patterns of individual cells as determined by time-lapse imaging. 
The migration paths of twenty randomly chosen HCT116 cells with stable expression of NRP1-WT, NRP1-
∆E4, NRP1-∆E5 or vector control were plotted as an x and y axis migration profile. (c) The net path lengths 
were quantified for the indicated HCT116 cells from (b). (d) Transwell migration analysis of HCT116 cells 
with stable expression of NRP1-WT, NRP1-∆E4, NRP1-∆E5 or vector control stimulated with VEGF165 (50 
ng ml-1), HGF (50 ng ml-1) or PBS control over 6 h of incubation. The results are expressed as the fold 
change of cell migration in the indicated cells relative to the vector control cells stimulated with PBS control. 
(e) Confocal images of NRP1 with DAPI staining in the primary Pt93 and LM2377 CRC cells transfected 
with two different sets of NRP1 siRNA or control siRNA for 48 h. Scale bars, 10 µm. (f, g) Pt93 and LM2377 
CRC cells were transfected with two different sets of NRP1 siRNA or control siRNA for 36 h, followed by 
transwell migration (f) and invasion (g) analyses. The results are expressed as a percentage of migrated 
or invaded cells found in siCtrl cells. All graphic data are presented as mean ± s.e.m. (n=3 independent 













































































Supplementary Figure 6. N-glycosylation-defective NRP1 regulates Met internalization and 
stabilization. (a) HT29 cells with stable expression of NRP1-WT, NRP1-ΔE4 or NRP1-ΔE5 were surface-
biotinylated and then the biotinylated proteins were pulled down by streptavidin beads. The total sample 
before pulldown (total), the supernatant corresponding to the intracellular fraction (unbound) and the 
surface fractions (bound) were analyzed by western blot using a Met antibody. (b) The percentage of 
intracellular Met was calculated as a ratio of the total. (c) The indicated primary CRC cells were lysed and 
immunoprecipitated with NRP1 antibody or IgG as control followed by western blot analysis. (d, e) Confocal 
images of NRP1, Met and DAPI staining in the indicated primary CRC cells (d) and HT29 cells with stable 
expression of NRP1-WT or the indicated mutants (e). Scale bars, 10 µm. (f) Confocal images of NRP1, 
Met and DAPI staining in serum-satrved HT29 cells with expression of the indicated NRP1 isoforms or 
mutants, stimulated with VEFG165 (50 ng ml-1), HGF (50 ng ml-1) or PBS as control for 30 min. Scale bars, 
10 µm. (g) HCT116 cells with expression of the indicated NRP1 isoforms or mutants were treated with 50 
μg ml-1 cycloheximide (CHX) for the indicated times followed by western blot analysis. (h) Western blots 
of Met as shown in (g) were quantified using Image J software. The level of Met remaining was obtained 
by normalizing to the β-actin level at each time point. Data are presented as mean ± s.e.m. (n=3 
independent experiments). *p < 0.001 using Student’s t-test. (i, j) NRP1-ΔE4- or NRP1-ΔE5-expressing 
HT29 cells were transfected with NRP1 siRNA or control siRNA for 48 h, followed by western blot analysis 
(i) or by confocal sections of the cells stained for NRP1 or Met with DAPI (j). Scale bars, 10 µm. (k) NRP1-
ΔE4- or NRP1-ΔE5-expressing HCT116 cells with stable expression of NRP1 shRNA were lysed and 
immunoprecipitated with Met antibody or IgG as control followed by western blot analysis. (l) NRP1-WT-, 
NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells with stable expression of Met shRNA were treated 
with 50 μg ml-1 cycloheximide (CHX) for the indicated times followed by western blot analysis. (m) Western 
blots of NRP1 as shown in (l) were quantified using Image J software. The level of NRP1 remaining was 
obtained by normalizing to the β-actin level at each time point. Data are presented as mean ± s.e.m. (n=3 






























Supplementary Fig. 7. β1-integrin co-internalizes with N-glycosylation-defective NRP1. (a, b) 
Confocal images of NRP1, β1-integrin and DAPI staining in the indicated primary CRC cells (a) and HT29 
cells with stable expression of NRP1-WT or the indicated mutants (b). Scale bars, 10 µm. (c) HCT116 cells 
with expression of the indicated NRP1 isoforms or mutants were treated with 50 μg ml-1 cycloheximide 
(CHX) for the indicated times followed by western blot analysis. (d) Western blots of Met as shown in (c) 
were quantified using Image J software. The level of Met remaining was obtained by normalizing to the β-
actin level at each time point. (e) NRP1-WT-, NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells with 
stable expression of β1-integrin shRNA were treated with 50 μg ml-1 cycloheximide (CHX) for the indicated 
times followed by western blot analysis. (f) Western blots of NRP1 as shown in (e) were quantified using 
Image J software. The level of NRP1 remaining was obtained by normalizing to the β-actin level at each 
time point. (g) NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells with stable expression of β1-integrin 
shRNA were lysed and immunoprecipitated with NRP1 antibody or IgG as control followed by western blot 
analysis.  All data are presented as mean ± s.e.m. (n=3 independent experiments). *p < 0.001 using 





Supplementary Fig. 8. NRP1-∆E4 and NRP1-∆E5 increase Rac1 activity to promote CRC cell 
migration. (a, b) HCT116 cells with stable expression of the indicated NRP1 isoforms or vector control 
were grown in the regular growth medium containing 10% FBS (a), or serum starved overnight followed 
by stimulation with HGF (50 ng ml-1) for 30 min (b), and subsequently assessed for the levels of Rac1-GTP 
and total Rac1. (c, d)  NRP1-WT-, NRP1-ΔE4- or NRP1-ΔE5-expressing HCT116 cells with stable 
expression of two different sets of Rac1 shRNA or control shRNA were assessed by western blot analysis 
(c), or by transwell migration analysis (d). The results are expressed as the fold change over the migrated 
cell number found in NRP1-WT cells expressed with shCtrl. Data are presented as mean ± s.e.m. (n=3 





Supplementary Fig. 9. Dynasore or silencing clathrin heavy chain (CHC) reduces the co-
internalization of β1-integrin with NRP1-∆E4 or NRP1-∆E5. (a) Confocal images of NRP1, β1-integrin 
and DAPI staining in HT29 cells with expression of the indicated NRP1 isoforms that were treated with 
dynasore (80 µM) or DMSO as control for 2 h. Scale bars, 10 µm. (b) Confocal images of NRP1, β1-
integrin and DAPI staining in HT29 cells with expression of the indicated NRP1 isoforms that were 











Supplementary Figure 10. The activity of FAK kinase, but not Met tyrosine kinase, is required for 
NRP1-∆E4- or NRP1-∆E5-stimulated cell migration and invasion. (a) HCT116 cells with stable 
expression of NRP1-WT, NRP1-ΔE4 or NRP1-ΔE5 were treated with 1 μM PHA-665752 or DMSO as 
control for 6 h, followed by western blot analysis. (b) Confocal images of Met with DAPI staining in serum-
starved HCT116 cells that were pretreated with 1 μM PHA-665752 or DMSO as control for 1 h, followed 
by stimulation with HGF (50 ng ml-1) for 30 min. Scale bars, 10 µm. (c) Confocal images of NRP1, Met, β1-
integrin and DAPI staining in HCT116 cells with expression of the indicated NRP1 isoforms, treated with 1 
μM PHA-665752 for 1 h. Scale bars, 10 µm. (d, e) Transwell migration (d) and invasion (e) analyses of 
HCT116 cells with expression of the indicated NRP1 isoforms in the presence of DMSO or 1 μM PHA-
665752 over 6 h and 30 h of incubation, respectively. The results are expressed as the fold change in cell 
migration or invasion in the indicated cells relative to the NRP1-WT-expressing cells treated with DMSO. 
(f-h) HCT116 cells with expression of the indicated NRP1 isoforms were treated with VS-6063 (1 µM) or 
DMSO for 6 h, followed by western blot analysis (f), or by transwell migration (g) and invasion (h) analyses. 
The results are expressed as the inhibition of migration or invasion relative to each of DMSO-treated control 
cells. (i, j) HCT116 cells with expression of the indicated NRP1 isoforms were transfected with two different 
sets of p130Cas siRNA or control siRNA for 48 h, followed by western blot analysis (i), or by transwell 
migration analysis (j). The results are expressed as the inhibition of migration relative to each of siCtrl cells. 
All graphic data are presented as mean ± s.e.m. (n=3 independent experiments). *p < 0.01; **p < 0.02 








Supplementary Figure 11. NRP1-∆E4 and NRP1-∆E5 co-localize with exosome markers. Confocal 
images of NRP1, CD63, CD81, Alix and DAPI staining in HCT116 or HT29 cells with expression of the 
indicated NRP1 isoforms. Scale bars, 10 µm.  
 
Supplementary Table 1. The use of CRC specimens in Figure 1e 
Specimen TNM Stage Pathology Source 
Pt93 T4bN2aM1a Invasive moderate to poorly 
differentiated colonic adenocarcinoma 
Markey Cancer Center, 
University of Kentucky 
Pt130 T4bN1 Metastatic colonic adenocarcinoma Markey Cancer Center, 
University of Kentucky 
Pt2377 T3N0M1a Metastatic colonic adenocarcinoma Markey Cancer Center, 
University of Kentucky 
LM2377 T3N0M1a Liver Metastases Markey Cancer Center, 
University of Kentucky 
NF90 T2N0M0 Villous colonic adenocarcinoma Nanfang Hospital, 
Southern Medical University 
NF99 T3N0M0  Tubule villous colonic 
adenocarcinoma 
Nanfang Hospital, Southern 
Medical University 
NF103 T3N0M0 Well differentiated colonic 
adenocarcinoma 
Nanfang Hospital,  
Southern Medical University 
NF105 T4N1aM1a Metastatic moderate to poorly 
differentiated colonic adenocarcinoma 
Nanfang Hospital,  
Southern Medical University 
NF106 T3N2M0 Metastatic moderate to poorly 
differentiated colonic adenocarcinoma 
Nanfang Hospital,  
Southern Medical University 
NF110 T3N0M0 Moderate differentiated colonic 
adenocarcinoma 
Nanfang Hospital,  


























Supplementary Table 2. Clinical characteristics of patients (n = 126) 
                                      Parameter Number (%) 
Age (yr) <60 64 
 >60 62 
Sex Male 73 (57.9%) 
 Female 53 (42.1%) 
Tumor location Colon 76 (60.3%) 
 Rectum 50 (39.7%) 
Differentiation Well 27 (21.4%) 
 Moderate 79 (62.7%) 
 Poor 20 (15.9%) 
Histologic type Adenocarcinoma 107 (84.9%) 
 Mucinous carcinoma 19 (15.1%) 
Stage I 30 (23.8%) 
 II 47 (37.3%) 
 III 29 (23.0%) 















Supplementary Table 3. siRNA and shRNA sequences used for targeting the indicated human 
genes 
Constructs Target sequences (5’-3’) 
NRP1 siRNA_1 AGATCGACGTTAGCTCCAA 
NRP1 siRNA_2 ATCAGAGTTTCCAACATAT 
Clathrin siRNA_1 AATCCAATTCGAAGACCAA 
Clathrin siRNA_2 GTATGATGCTGCTAAACTA 
FAK siRNA_1 CGGTCGAATGATAAGGTGT 
FAK siRNA_2 CCCAGGTTTACTGAACTTA 
p130Cas siRNA_1 GGTCGACAGTGGTGTGTAT 
p130Cas siRNA_2 GGATGGAGGACTATGACTA 
NRP1 shRNA TGTGGATGACATTAGTATTAA 
Met shRNA_1 GTGTGTTGTATGGTCAATAAC 
Met shRNA_2 CCTTCAGAAGGTTGCTGAGTA 
β1-integrin shRNA_1 GCCCTCCAGATGACATAGAAA 
β1-integrin shRNA_2 TAGGTAGCTTTAGGGCAATAT 
Rac1 shRNA_1 CGCAAACAGATGTGTTCTTAA 
Rac1 shRNA_2 CGTGAAGAAGAGGAAGAGAAA 

















Supplementary Table 4. Antibodies used for immunofluorescence (IF), western blot (WB) and 
immunoprecipitation (IP) analyses  




Goat polyclonal Santa Cruz Biotechnology sc-7239 
Anti-NRP1 IF: 1:100 Sheep polyclonal R&D Systems AF3870 
Anti-NRP1 IP: 1:50 Mouse monoclonal Santa Cruz Biotechnology sc-5307 
Anti-NRP1 WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 3725 




Rabbit monoclonal Cell Signaling Technology 8198 
Anti-p-Met 
(Tyr1234/1235) 
WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 3077 
Anti-p-Met (Tyr1349) WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 3133 
Anti-EGFR WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 4267 
Anti-VEGFR2 WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 2479 
Anti-AKT WB: 1:1000 Rabbit polyclonal Cell Signaling Technology 9272 
Anti-p-Akt (Ser473) WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 4060 
Anti-ERK1/2 WB: 1:1000 Rabbit polyclonal Cell Signaling Technology 9102 
Anti-p-ERK1/2 
(Thr202/Tyr204) 
WB: 1:1000 Rabbit polyclonal Cell Signaling Technology 9101 
Anti-FAK WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 13009 
Anti-p-FAK (Tyr397) WB: 1:1000 Rabbit monoclonal Cell Signaling Technology 8556 
Anti-p-FAK (Tyr397) IF: 1:100 Rabbit polyclonal ThermoFisher 44-624G 
Anti-p130Cas WB: 1:1000 Mouse monoclonal Santa Cruz Biotechnology sc-20029 
Anti-p-p130Cas 
(Tyr249) 
WB: 1:1000 Rabbit polyclonal Cell Signaling Technology 4014 
Anti-Clathrin heavy 
chain 





Mouse monoclonal Abcam ab30394 
Anti-α6-integrin IF: 1:100 Rat monoclonal Santa Cruz Biotechnology sc-19622 
Anti-β-actin WB: 1:10,000 Mouse monoclonal Sigma A5441 
Anti-EEA1 IF: 1:100 Rabbit monoclonal Cell Signaling Technology 3288 
Anti-Rab7 IF: 1:100 Rabbit monoclonal Cell Signaling Technology 9367 
Anti-Rab7 IF: 1:100 Mouse monoclonal Cell Signaling Technology 95746 
Anti-Rab4  IF: 1:50 Rabbit polyclonal Bioss bs-6157R 
Anti-Rab11 IF: 1:100 Rabbit monoclonal Cell Signaling Technology 5589 
Anti-Cathepsin D IF: 1:100 Mouse monoclonal Santa Cruz Biotechnology sc-377124 
Anti-GIPC1 WB: 1:1000 Mouse monoclonal Santa Cruz Biotechnology sc-271822 
Anti-Rac1 WB: 1:1000 Mouse monoclonal BD Biosciences 610651 
Anti-CD63 IF: 1:50 Mouse monoclonal Santa Cruz Biotechnology sc-5275 
Anti-CD81 IF: 1:50 Mouse monoclonal Santa Cruz Biotechnology sc-166029 
Anti-Alix IF: 1:50 Mouse monoclonal Santa Cruz Biotechnology sc-53540 
Anti-goat IgG with 
Alexa Fluor 488 





Anti-goat IgG with 
TRITC 





Anti-sheep IgG with 
Alexa Fluor 594 





Anti-rat IgG with 
Alexa Fluor 488 





Anti-rabbit IgG with 
TRITC 





Anti-mouse IgG with 
TRITC 





Anti-rabbit IgG with 
Cyanine Cy5 





Anti-mouse IgG with 
Cyanine Cy5 
IF: 1:500 Goat polyclonal 
Jackson 
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